Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy
Wissam Ghusn·Omar M. Ghanem·Noura Jawhar·Tala Abedalqader·Nour El Ghazal·Maria Antonia Espinosa·Jose Villamarin·Rene Rivera Gutierrez·Regina Castaneda·Dima Bechenati·Sima Fansa·Maria D. Hurtado·Andres Acosta·Robert A. Vierkant
Objective: To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity. Summary Background Data: Obesity is a major driver of ASCVD through adverse metabolic and inflammatory pathways. Metabolic and bariatric surgery and GLP-1 receptor agonists represent the most effective contemporary treatments for obesit